대한의생명과학회지 (Biomedical Science Letters)

  • 제27권4호
  • /
  • Pages.208-215
  • /
  • 2021
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

A Review on the Correlation between the Pathology of Alzheimer's Disease and microRNA

  • Kim, Soo-Jung (Department of Biomedical Laboratory Science, College of Medical Science, Konyang University) ;
  • Cho, Hyun-Jeong (Department of Biomedical Laboratory Science, College of Medical Science, Konyang University)
  • 투고 : 2021.10.28
  • 심사 : 2021.12.10
  • 발행 : 2021.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The purpose of this study was to explain the pathology of Alzheimer's disease (AD) and to investigate the correlation between AD and microRNA. AD is the most common type of dementia, accounting for about 80% of all types of dementia, causing dysfunction in various daily activities such as memory loss, cognitive impairment, and behavioral impairment. The typical pathology of AD is explained by the accumulation of beta-amyloid peptide plaques and neurofibrillary tangles containing hyperphosphorylated tau protein. On the other hand, microRNA is small non-coding RNA 22~23 nucleotides in length that binds to the 3' untranslated region of messenger RNA to inhibit gene expression. Many reports explain that microRNAs found in circulating biofluids are abundant in the central nervous system, are involved in the pathogenic mechanism of AD, and act as important factors for early diagnosis and therapeutic agents of AD. Therefore, this paper aims to clarify the correlation between AD and microRNA. In this review, the basic mechanism of miRNAs is described, and the regulation of miRNAs in the pathological processes of AD are highlighted. Furthermore, we suggest that miRNA-based system in development of therapeutic and diagnostic agents of AD can be a promising tool.

키워드

참고문헌

  1. Amakiri N, Kubosumi A, Tran J, Reddy PH. Amyloid Beta and MicroRNAs in Alzheimer's Disease. Front Neurosci. 2019. 3: 430.
  2. Angelucci F, Cechova K, Valis M, Kuca K, Zhang B, Hort J. MicroRNAs in Alzheimer's Disease: Diagnostic Markers or Therapeutic Agents? Front Pharmacol. 2019. 10: 665. https://doi.org/10.3389/fphar.2019.00665
  3. Athanasopoulos D, Karagiannis G, Tsolaki M. Recent Findings in Alzheimer Disease and Nutrition Focusing on Epigenetics. Adv Nutr. 2016. 7: 917-927. https://doi.org/10.3945/an.116.012229
  4. Auso E, Gomez-vicente V, Esquiva G. Biomarkers for Alzheimer's Disease Early Diagnosis. J Pers Med. 2020. 10: 114. https://doi.org/10.3390/jpm10030114
  5. Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules. 2020. 25: 5789. https://doi.org/10.3390/molecules25245789
  6. Canepa E, Fossati S. Impact of Tau on Neurovascular Pathology in Alzheimer's Disease. Front Neurol. 2021. 11: 573324. https://doi.org/10.3389/fneur.2020.573324
  7. Cheignon C, Tomas M, Bonnefont-rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 2018. 14: 450-464. https://doi.org/10.1016/j.redox.2017.10.014
  8. Chen F, Chen H, Jia Y, Lu H, Tan Q, Zhou X. miR-149-5p inhibition reduces Alzheimer's disease β-amyloid generation in 293/APPsw cells by upregulating H4K16ac via KAT8. Exp Ther Med. 2020. 20: 88.
  9. Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol. 2018. 14: 399-415. https://doi.org/10.1038/s41582-018-0013-z
  10. Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer's disease drug development pipeline: 2020. Alzheimers Dement. 2020. 6: e12050.
  11. Deng Y, Zhang J, Ma GMa G et al. miR-132 improves the cognitive function of rats with Alzheimer's disease by inhibiting the MAPK1 signal pathway. Exp Ther Med. 2020. 20: 159. https://doi.org/10.3892/etm.2020.9288
  12. Eyileten C, Sharif L, Wicik ZWicik Z et al. The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke. Mol Neurobiol. 2021. 58: 329-347. https://doi.org/10.1007/s12035-020-02101-2
  13. FracassI A, MarcattI M, Zolochevska OZolochevska O et al. Oxidative Damage and Antioxidant Response in Frontal Cortex of Demented and Nondemented Individuals with Alzheimer's Neuropathology. J Neurosci. 2021. 41: 538-554. https://doi.org/10.1523/JNEUROSCI.0295-20.2020
  14. Ghini F, Rubolino C, Climent M, Simeone I, Marzi MJ, Nicassio F. Endogenous transcripts control miRNA levels and activity in mammalian cells by target-directed miRNA degradation. Nat Commun. 2018. 9: 3119. https://doi.org/10.1038/s41467-018-05182-9
  15. Goedert M. Tau filaments in neurodegenerative diseases. FEBS Lett. 2018. 592: 2383-2391. https://doi.org/10.1002/1873-3468.13108
  16. Guan P, Cao L, Wang P. Elevating the Levels of Calcium Ions Exacerbate Alzheimer's Disease via Inducing the Production and Aggregation of β-Amyloid Protein and Phosphorylated Tau. Int J Mol Sci. 2021. 22: 5900. https://doi.org/10.3390/ijms22115900
  17. Gugliandolo A, Chiricosta L, BoccardI V, Mecocci P, Bramanti P, Mazzon E. MicroRNAs Modulate the Pathogenesis of Alzheimer's Disease: An In Silico Analysis in the Human Brain. Genes. 2020. 11: 983. https://doi.org/10.3390/genes11090983
  18. Guo Y, Wu Y, Li N, Wang Z. Up-regulation of miRNA-151-3p enhanced the neuroprotective effect of dexmedetomidine against β-amyloid by targeting DAPK-1 and TP53. Exp Mol Pathol. 2021. 118: 104587. https://doi.org/10.1016/j.yexmp.2020.104587
  19. Hamano T, Enomoto S, Shirafuji NShirafuji N et al. Autophagy and Tau Protein. Int J Mol Sci. 2021. 22: 7475. https://doi.org/10.3390/ijms22147475
  20. Hara N, Kikuchi M, Miyashita AMiyashita A et al. Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease. Acta Neuropathol Commun. 2017. 5: 10. https://doi.org/10.1186/s40478-017-0414-z
  21. Huang Y, Mucke L. Alzheimer Mechanisms and Therapeutic Strategies. Cell. 2012. 148: 1204-1222. https://doi.org/10.1016/j.cell.2012.02.040
  22. Improta-Caria AC, Nonaka CKV, Cavalcante BRRCavalcante BRR et al. Modulation of MicroRNAs as a Potential Molecular Mechanism Involved in the Beneficial Actions of Physical Exercise in Alzheimer Disease. Int J Mol Sci. 2020. 21: 4977. https://doi.org/10.3390/ijms21144977
  23. Jaber VR, Zhao Y, Sharfman NM, Li W, Lukiw WJ. Addressing Alzheimer's Disease (AD) Neuropathology Using Anti-microRNA (AM) Strategies. Mol Neurobiol. 2019. 56: 8101-8108. https://doi.org/10.1007/s12035-019-1632-0
  24. Jiang L, Dong H, Cao H, Ji X, Luan S, Liu J. Exosomes in Pathogenesis, Diagnosis, and Treatment of Alzheimer's Disease. Med Sci Monit. 2019. 25: 3329-3335. https://doi.org/10.12659/msm.914027
  25. Kent SA, Spires-Jones TL, Durrant CS. The physiological roles of tau and Aβ: implications for Alzheimer's disease pathology and therapeutics. Acta Neuropathological. 2020. 140: 417-447. https://doi.org/10.1007/s00401-020-02196-w
  26. Kim E, Otgontenger U, Jamsranjav A, Kim SS. Deleterious Alteration of Glia in the Brain of Alzheimer's Disease. Int J Mol Sci. 2020. 21: 6676. https://doi.org/10.3390/ijms21186676
  27. Koh HS, Lee SJ, Lee HJLee HJ et al. Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression. Int J Mol Sci. 2021. 22: 13136. https://doi.org/10.3390/ijms222313136
  28. Kumar S, Reddy AP, Yin XYin X et al. Novel MicroRNA-455-3p and its Protective Effects Against Abnormal APP Processing and Amyloid Beta Toxicity in Alzheimer's Disease. Biochim Biophys Acta Mol Basis Dis. 2019. 1865: 2428-2440. https://doi.org/10.1016/j.bbadis.2019.06.006
  29. Kumar S, Reddy PH. Are circulating microRNAs peripheral biomarkers for Alzheimer's disease? Biochim Biophys Acta. 2016. 1862: 1617-1627. https://doi.org/10.1016/j.bbadis.2016.06.001
  30. Kumar S, Reddy PH. MicroRNA-455-3p as a Potential Biomarker for Alzheimer's Disease: An Update. Front Aging Neurosci. 2018. 10: 41. https://doi.org/10.3389/fnagi.2018.00041
  31. Li J, Salvador AM, Li GLi G et al. Mir-30d Regulates Cardiac Remodeling by Intracellular and Paracrine Signaling. Circ Res. 2021. 128: e1-e23.
  32. Liu X, Wang H, Bei J, Zha J, Jiang G, Liu X. The protective role of miR-132 targeting HMGA2 through the PI3K/AKT pathway in mice with Alzheimer's disease. Am J Transl Res. 2021. 13: 4632-4643.
  33. Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018. 141: 1202-1207. https://doi.org/10.1016/j.jaci.2017.08.034
  34. Lukiw WJ, Vergallo A, Lista S, Hampel H, Zhao Y. Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. J Pers Med. 2020. 10: 138. https://doi.org/10.3390/jpm10030138
  35. Madadi S, Schwarzenbach H, Saidijam M, Mahjub R, Soleimani M. Potential microRNA-related targets in clearance pathways of amyloid-β: novel therapeutic approach for the treatment of Alzheimer's disease. Cell Biosci. 2019. 9: 91. https://doi.org/10.1186/s13578-019-0354-3
  36. Manna I, De Benedittis S, Quattrone A, Maisano D, Iaccino E, Quattrone A. Exosomal miRNAs as Potential Diagnostic Biomarkers in Alzheimer's Disease. Pharmaceuticals. 2020. 13: 243. https://doi.org/10.3390/ph13090243
  37. Mantzavinos V, Alexiou A. Biomarkers for Alzheimer's Disease Diagnosis. Curr Alzheimer Res. 2017. 14: 1149-1154.
  38. Michalicova A, Majerova P, Kovac A. Tau Protein and Its Role in Blood-Brain Barrier Dysfunction. Front Mol Neurosci. 2020. 13: 570045. https://doi.org/10.3389/fnmol.2020.570045
  39. Nasaruddin ML, Syarifah ASAH, Kamaruzzaman MA. Studying the Relationship of Intermittent Fasting and β-Amyloid in Animal Model of Alzheimer's Disease: A Scoping Review. Nutrients. 2020. 12: 3215. https://doi.org/10.3390/nu12103215
  40. Naseri NN, Wang H, Guo J, Sharma M, Luo W. The complexity of tau in Alzheimer's disease. Neurosci Lett. 2019. 705: 183-194. https://doi.org/10.1016/j.neulet.2019.04.022
  41. Prendecki M, Dorszewska J. The role of MicroRNA in the pathogenesis and diagnosis of neurodegenerative diseases. Austin Alzheimers J. Parkinsons Dis. 2014. 1: 10.
  42. Pirscoveanu DFV, Pirici I, Tudorica VTudorica V et al. Tau protein in neurodegenerative diseases - a review. Rom J Morphol Embryol. 2017. 58: 1141-1150.
  43. Rabbito A, Dulewicz M, Kulczynska-przybik A, Mroczko B. Biochemical Markers in Alzheimer's Disease. Int J Mol Sci. 2020. 21: 1989. https://doi.org/10.3390/ijms21061989
  44. Rasgado LAV, Urbieta AT, Jimenez JMM. Affected albumin endocytosis as a new neurotoxicity mechanism of amyloid beta. AIMS neurosci. 2020. 7: 344-359. https://doi.org/10.3934/Neuroscience.2020021
  45. Santa-Maria I, Alaniz ME, Renwick NRenwick N et al. Dysregulation of microRNA-219 promotes neurodegeneration through post-transcriptional regulation of tau. J Clin Invest. 2015. 125: 681-686. https://doi.org/10.1172/JCI78421
  46. Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021. 20: 68-80. https://doi.org/10.1016/s1474-4422(20)30412-9
  47. Sheinerman KS, Toledo JB, Tsivinsky VGTsivinsky VG et al. Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimer's Res Ther. 2017. 9: 89. https://doi.org/10.1186/s13195-017-0316-0
  48. Shi L, Zhang R, Li TLi T et al. Decreased miR-132 plays a crucial role in diabetic encephalopathy by regulating the GSK-3β/Tau pathway. Aging. 2020. 13: 4590-4604.
  49. Soares Martins T, Trindade D, Vaz MVaz M et al. Diagnostic and therapeutic potential of exosomes in Alzheimer's disease. J Neurochem. 2021. 156: 162-181. https://doi.org/10.1111/jnc.15112
  50. Swarbrick S, Wragg N, Ghosh S, Stolzing A. Systematic Review of miRNA as Biomarkers in Alzheimer's Disease. Mol Neurobiol. 2019. 56: 6156-6167. https://doi.org/10.1007/s12035-019-1500-y
  51. Van Giau V, An SS. Emergence of exosomal miRNAs as a diagnostic biomarker for Alzheimer's disease. J Neurol Sci. 2016. 360: 141-152. https://doi.org/10.1016/j.jns.2015.12.005
  52. Vergallo A, Lista S, Zhao YZhao Y et al. MiRNA-15b and miRNA-125b are associated with regional Aβ-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. Transl Psychiatry. 2021. 11: 78. https://doi.org/10.1038/s41398-020-01184-8
  53. Wang M, Qin L, Tang B. MicroRNAs in Alzheimer's Disease. Front Genet. 2019. 10: 153. https://doi.org/10.3389/fgene.2019.00153
  54. Wang X, Zhou Y, Gao QGao Q et al. The Role of Exosomal microRNAs and Oxidative Stress in Neurodegenerative Diseases. Oxid Med Cell Longev. 2020. 3232869.
  55. Wei W, Wang ZY, Ma LN, Zhang TT, Cao Y, Li H. MicroRNAs in Alzheimer's Disease: Function and Potential Applications as Diagnostic Biomarkers. Front Mol Neurosci. 2020. 13: 160. https://doi.org/10.3389/fnmol.2020.00160
  56. Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment. F1000 Res. 2018. 7: Faculty Rev-1161.
  57. Wilkins HM, Swerdlow RH. Amyloid precursor protein processing and bioenergetics. Brain Res Bull. 2017. 133: 71-79. https://doi.org/10.1016/j.brainresbull.2016.08.009
  58. Wu HZY, Thalamuthu A, Cheng LCheng L et al. Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer's disease and controls. Alzheimer's Res Ther. 2020. 12: 59. https://doi.org/10.1186/s13195-020-00627-0
  59. Yang TT, Liu CG, Gao SC, Zhang Y, Wang PC. The Serum Exosome Derived MicroRNA-135a, -193b, and -384 Were Potential Alzheimer's Disease Biomarkers. Biomed Environ Sci. 2018. 31: 87-96.
  60. Yu L, Li H, Liu WLiu W et al. MiR-485-3p serves as a biomarker and therapeutic target of Alzheimer's disease via regulating neuronal cell viability and neuroinflammation by targeting AKT3. Mol Genet Genomic Med. 2021. 9: e1548.
  61. Zetterberg H, Burnham SC. Blood-based molecular biomarkers for Alzheimer's disease. Mol Brain. 2019. 12: 26. https://doi.org/10.1186/s13041-019-0448-1
  62. Zhao Y, Hampel H, Vergallo A, Lista S, Lukiw WJ. Biomarkers for Alzheimer's Disease (AD) and the Application of Precision Medicine. J Pers Med. 2020. 10: 138. https://doi.org/10.3390/jpm10030138
  63. Zhao Y, Jaber V, Alexandrov PNAlexandrov PN et al. microRNA-Based Biomarkers in Alzheimer's Disease. Front Neurosci. 2020. 14: 585432. https://doi.org/10.3389/fnins.2020.585432
  64. Zhou Q, Luo L, Wang X, Li X. Relationship between single nucleotide polymorphisms in the 3'UTR of amyloid precursor protein and risk of Alzheimer's disease and its mechanism. Biosci Rep. 2019. 39: BSR20182485. https://doi.org/10.1042/BSR20182485